IlluminOss Medical has completed patient enrollment in its first US clinical trial in a bid to seek approval from the US Food and Drug Administration (FDA) for its IlluminOss System to treat fractures using patient-specific intramedullary implants.

The trial will be conducted across 13 surgical sites and will include 80 patients with fractures in the humerus due to metastatic carcinoma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

University of Pittsburgh Medical Center musculoskeletal oncology chief Dr Richard McGough said: “We have seen that the IlluminOss implant can be a game changer for patients with humeral metastatic disease.

"This technology allows us to stabilise the bone with less pain, less surgical time, and less difficulty for the patients."

“This technology allows us to stabilise the bone with less pain, less surgical time, and less difficulty for the patients.

“We can therefore treat this problem on an outpatient basis in some patients, and can condense treatments fairly dramatically.”

The device involves a minimally invasive procedure which uses a thin walled PET balloon that contains liquid monomer being inserted into the intramedullary canal of the bone assuming the shape of the patient’s specific bone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It creates a tough implant after the surgeon activates the visible light delivered within the PET balloon.

It imparts longitudinal strength and rotational stability across the length of the implant.

Memorial Sloan Kettering Cancer Center Stephen McDermott Chair in Surgery orthopaedic service chief Dr John Healey said: “The IlluminOss System is a transformative technology, providing versatility in the way advanced fracture repair can be approached and enabling orthopedic surgeons to extend the functional benefits of surgical stabilisation to more patients while also allowing them to preserve the rotator cuff.”

Till date, more than 1,500 patients across the world have been treated with the IlluminOss System resulting in rapid post-procedure patient mobility with smaller incisions and shorter procedure times.